The latest news: Bristol-Myers’ checkpoint star Opdivo fails a PhIII study for glioblastoma I did not really expect it to do well by itself. I feel that it may be part of a combination approach with other immune therapies. We are funding such a combination trial now! DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting This is one of my favorites. It may become a drop in replacement for Temodar in patients who have unmethylated MGMT, and it might also do better in other situations. BrainTumor Co-Payment Assistance Program Status: CLOSED to new applicants
